Data have revealed interactions between baseline concentration of hs-CRP an
d the efficacy of common pharmacologic therapies in primary and secondary p
revention, suggesting not only that it may be possible to modify the increa
sed risk associated with elevated hs-CRP, but also that inflammatory marker
s may be useful in targeting preventive therapies, inflammatory markers may
become a valuable component of routine cardiovascular risk assessment.